Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Exosome-Based Therapy: A Comparative Study of Adipose- and Umbilical Cord-Derived Mesenchymal Stem Cells-Derived Exosomes in Psoriatic Mouse Model.

Siriphanit R., Thanasarnaksorn W., Boonpethkaew S., Ponnikorn S., Charoensuksira S., Deenonpoe R.

Animal Study on Chronic Inflammation, published in Exp Dermatol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Exp Dermatol (2025)
Country
Denmark
Reported sample size
—
Source database
PubMed
PMID
41217063
DOI
10.1111/exd.70176

Abstract (original English)

Exosomes are nanosized extracellular vesicles that mediate intercellular communication by transferring bioactive molecules. Mesenchymal stem cells (MSCs) from different tissue sources secrete exosomes with potentially distinct therapeutic properties. In this study, we compared the anti-inflammatory efficacy of exosomes derived from human adipose-derived MSCs (hADMSCs-EXOs) and human umbilical cord-derived MSCs (hUCMSCs-EXOs), together with desoximetasone (DSM), in an imiquimod-induced psoriasis mouse model. Psoriasiform lesions were induced, and treatment outcomes were assessed through clinical, histological, and immunological assessments. Both hADMSCs-EXOs and hUCMSCs-EXOs significantly attenuated psoriasiform lesions, as clinically evidenced by reduced cumulative Psoriasis Severity Index (PSI) scores by day 6 of treatment. Notably, hUCMSCs-EXOs and DSM significantly reduced epidermal and dermal thickness to no significant difference compared to the control group. Immune cell infiltration, including CD3 + , CD4 + , CD8 + T cells, CD68 + macrophages, CD117 + mast cells, and neutrophils, was also markedly reduced in the hUCMSCs-EXOs and DSM groups. Importantly, unlike DSM, hUCMSCs-EXOs did not induce skin thinning or systemic adverse effects. Growth factor (GF) profiling revealed that hADMSCs-EXOs were enriched in FGFs, PDGFs, and VEGF, whereas hUCMSCs-EXOs contained higher leve

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ExosomesAnimalsPsoriasisMesenchymal Stem CellsHumansUmbilical CordDisease Models, AnimalAdipose TissueMiceMesenchymal Stem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research